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Introduction

Case

Progressive multifocal leukoencephalopathy
(PML) is a debilitating neurological
condition caused by the opportunistic
John Cunningham Virus (JCV). Clinical
manifestations traditionally develop with
severely immunosuppressed states. The
AIDS pandemic led to a preponderance of
PML diagnoses in patients with CD4 counts
less than 200/microliter. The advent of
HAART dramatically improved the morbidity
and mortality among patients within the last
decades. However, antiretroviral therapy
may paradoxically lead to the development
of PML in the setting of an immune
reconstitution inflammatory syndrome (PML1
IRIS).
Traditional diagnosis involved brain
biopsy, revealing the pathognomonic triad
of oligodendroglial nuclear inclusions,
2
demyelination, and bizarre astrocytes. More
recently, the diagnosis can be made based
on a constellation of clinical, radiologic,
and laboratory findings. Clinicians should
suspect PML in any immunosuppressed
patient presenting with neurologic signs and
symptoms. The most efficacious imaging
modality is an MRI of the brain with and
without gadolinium; traditional findings
include hyperintense lesions on T2-weighted
and FLAIR images, hypointense lesions
on T1-weighted images, and may include
5
gadolinium enhancement. Although findings
typically involve multifocal subcortical white
matter areas, lesions can also be monofocal
and involve atypical sites such as the
3
cerebellum. Cerebrospinal fluid analysis
(CSF) using a high-sensitivity polymerase
chain reaction (PCR) assay reveals elevated
JCV levels.
Risk factors associated with PML-IRIS
include prior exposure to the JCV, a low CD4
count, a low HIV load, a higher baseline CD8
cell count, a history of multiple opportunistic
infections, and the initiation of antiretroviral
therapy in close proximity to the onset of
1
the opportunistic infection. Unfortunately,
treatment options are limited. However,
there are few studies demonstrating the
clinical efficacy of steroids, particularly in
1
patients with PML-IRIS.

A 66-year-old female immigrant from Kenya with AIDS presented with progressively worsening ataxia. The patient was initially
diagnosed with AIDS upon discovery of pulmonary tuberculosis in August 2013, for which she completed a nine-month course
of treatment. She has since been on a fixed-dose combination therapy of Efavirenz, Tenofovir, and Emtricitabine. Her most recent
CD4 count was 61/microliter, with a viral load of 25 copies/mL. She had developed a wide-based ataxic gait and left-sided deficits
approximately 10 months after beginning antiretroviral therapy. An MRI of the brain with and without gadolinium revealed a 18mm
focal area of T2-hyperintensity in the right middle cerebellar peduncle, along with prominent cerebellar leptomeningeal enhancement.
Cerebrospinal fluid analysis revealed 1400 DNA copies/mL of the JC Virus. The patient’s progressive ataxia, low CD4 count, significant
JC Virus positivity in the CSF, and MRI findings led to the diagnosis of PML. Because her neurologic symptoms began approximately 10
months after beginning therapy, a more definite diagnosis of PML-IRIS was made, which can present up to 26 months after beginning
1
antiretroviral therapy. The patient was promptly begun on high-dose intravenous steroid therapy for symptomatic relief.
Diagnostic Algorithm
Neurologic Symptoms
in an
Immunosuppressed
Patient

Evaluate/Rule-Out
Common Etiologies

Serum Studies
Absolute Lymphocytes
% CD3
Absolute CD3

No MRI Findings

Unlikely PML

Typical MRI Findings

Cerebrospinal Fluid
Analysis for JC Virus

MRI Brain with and
without Gadolinium
Definite PML

Cerebrospinal Fluid
2.12

RBC

16 (Ref: 0/cm)

69

WBC

88 (Ref: 0-5/cm)

Neutrophils

0 (Ref: 0-6%)

1443

% CD4

3

Lymphocytes

96% (Ref: 40-80%)

Absolute CD4

61

Monocytes

4% (Ref: 14-45%)

% CD8

65

Glucose

57 (Ref: 40-70mg/dL)

Absolute CD8

1353

Protein

120 (Ref: 15-45mg/dL)

CD4/CD8

0.04

TB Culture

Negative

Viral Load

25

Epstein Barr Virus PCR

Negative

Bacterial Culture

No growth

Listeria

Negative

Cryptococcal Antigen

Negative by Latex Agglutination

Cytology

No Clonal Proliferation

JC Virus PCR

1400 DNA Copies/mL

18mm focal area of T2 hyperintensity in the right middle
cerebellar peduncle with prominent leptomeningeal
enhancement involving the cerebellum.

Key Points
•C
 linicians must maintain a high index of suspicion for PML in any immunosuppressed patient presenting with new or worsening
4
neurologic signs or symptoms.
• Implementation of antiretroviral therapy in AIDS patients does not exclude the possibility of PML.
• T he diagnosis of PML incorporates a constellation of clinical, radiographic, and laboratory data. A pathologic diagnosis is not mandatory.
•M
 RI with and without gadolinium is the image of choice, and any focal or nonfocal finding may suggest PML.
•C
 SF analysis for the JC Virus is essential in diagnosing PML.
• P rompt diagnosis is crucial, as implementing steroid therapy may slow progression of the disease, and may lead to clinical improvement.
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